Characterization of patients with androgen-independent prostatic carcinoma whose serum prostate specific antigen decreased following flutamide withdrawal

Journal of Urology

Volumn 155, Issue 2, 1996, Pages 620-623

  Herrada, Juan ^a   Dieringer, Pauline ^a   Logothetis, Christopher J ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

antigens, neoplasm; flutamide; prostate specific antigen; prostatic neoplasms

Indexed keywords

ANDROGEN; ANDROSTENEDIONE; BOMBESIN; FLUTAMIDE; PRASTERONE; PRASTERONE SULFATE; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ADULT; AGED; ANDROGEN METABOLISM; ARTICLE; CANCER HORMONE THERAPY; CASTRATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG WITHDRAWAL; HUMAN; HUMAN TISSUE; MALE; PATIENT SELECTION; PRIORITY JOURNAL; PROSTATE CARCINOMA; TESTOSTERONE BLOOD LEVEL; TUMOR GROWTH;

EID: 0030040676     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)66468-1     Document Type: Article

References (19)

1. Byar, D. P.: Proceedings: The Veterans Administration Cooperative Urological Research Group's studies of cancer of the prostate. Cancer, 32: 1126, 1973.
2. Scott, W. W., Menon, M. and Walsh, P. C.: Hormonal therapy of prostatic cancer. Cancer, suppl., 45: 1929, 1980.
3. Eisenberger, M. A., O'Dwyer, P. J. and Friedman, M. A.: Gonadotropin hormone-releasing hormone analogues: a new therapeutic approach for prostatic carcinoma. J. Clin. Oncol., 4: 414, 1986.
4. Leuprolide versus diethylstilbestrol for metastatic prostate cancer. The Leuprolide Study Group. New Engl. J. Med., 311: 1281, 1984.
5. Crawford, E. D., Eisenberger, M. A., McLeod, D. G., Spaulding, J. T., Benson, R., Dorr, F. A., Blumenstein, B. A., Davis, M. A. and Goodman, P. J.: A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. New Engl. J, Med., 321: 419, 1989.
6. Tannock, I., Gospodarowicz, M., Meakin, W., Panzarella, T., Stewart, L. and Rider, W.: Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response. J. Clin. Oncol., 7: 590, 1989.
7. Scher, H. I. and Kelly, W. K.: Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer. J. Clin. Oncol., 11: 1566, 1993.
8. Kelly, W. K. and Scher, H. I.: Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome. J. Urol., 149: 607, 1993.
9. Dupont, A., Gomez, J.-L., Cusan, L., Koutsilieris, M. and Labrie, F.: Response to flutamide withdrawal in advanced prostate cancer in progression under combination therapy. J. Urol., 150: 908, 1993.
10. Wilson, A. J.: Response in breast cancer to a second hormonal therapy. Rev. Endocr. Related Cancer, 14: 5, 1983.
11. Canney, P. A., Griffiths, T., Latief, T. N. and Priestman, T. J.: Clinical significance of tamoxifen withdrawal response. Lancet, 1: 36, 1987.
12. Balzano, S., Cappa, M., Migliari, R., Scarpa, R. M., Danielli, E., Campus, G., Pintus, C., Sica, V., Usai, E. and Martino, E.: The effect of flutamide on basal and ACTH-stimulated plasma levels of adrenal androgens in patients with advanced prostate cancer. J. Endocr. Invest., 11: 693, 1988.
13. Secreto, G., Recchione, C., Zambetti, M., Fariselli, G. and Ballerini, P.: Hormonal changes induced by the pure antiandrogen flutamide in postmenopausal women with advanced breast cancer. Eur. J. Cancer Clin. Oncol., 24: 867, 1988.
14. Correa, R., Arteaga, E., Lopez, X., Arteaga, A., Fernandez, C. and Acosta, A. M.: The effect of a peripheral androgenic blockade on plasma lipoproteins in hirsutism patients. Rev. Med. Chile, 118: 1362, 1990.
15. Fruzzetti, F., De Lorenzo, D., Ricci, C. and Fioretti, P.: Clinical and endocrine effects of flutamide in hyperandrogenic women. Fertil. Steril., 60: 806, 1993.
16. Labrie, F.: Mechanism of action and pure antiandrogenic properties of flutamide. Cancer, suppl., 72: 3816, 1993.
17. Neri, R. O.: Antiandrogens. Adv. Sex Hormone Res., 2: 233, 1976.
18. Schuurmans, A. L., Bolt, J., Veldscholte, J. and Mulder, E.: Stimulatory effects of antiandrogens on LNCaP human prostate tumor cell growth, EGF-receptor level and acid phosphatase secretion. J. Steroid Biochem. Molec. Biol., 37: 849, 1990.
19. Veldscholte, J., Ris-Stalpers, C., Kuiper, G. G. J. M., Jenster, G., Berrevoets, C., Claassen, E., van Rooij, H. C. J., Trapman, J., Brinkman, A. O. and Mulder, E.: A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to antiandrogens. Biochem. Biophys. Res. Comm., 173: 534, 1990.